Tesorai
AI platform for mass spectrometry proteomics data analysis, enabling searchable and structured insights for life sciences.
Website: https://www.tesorai.com/
Cover Block
From the public record
| Field | Detail |
|---|---|
| Name | Tesorai |
| Tagline | AI platform for mass spectrometry proteomics data analysis, enabling searchable and structured insights for life sciences [tesorai.com] |
| Headquarters | San Diego, US [Genetic Engineering & Biotechnology News, November 2026] |
| Founded | 2024 [Genetic Engineering & Biotechnology News, November 2026] |
| Stage | Seed [Crunchbase] |
| Business model | SaaS |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+): Melissa Miao, Peter Cimermancic, Charlie Kim [Genetic Engineering & Biotechnology News, November 2026] |
| Funding label | Seed |
| Total disclosed funding | Approximately $8,000,000 [WFMZ / PR Newswire, November 2026] |
Links
From the public record
- Website: https://www.tesorai.com/
- Careers: https://www.tesorai.com/company/careers
The Short Version
PUBLIC Tesorai is building an AI software platform that converts raw proteomics and related molecular research data into searchable, structured outputs, a timely proposition as drug discovery teams and biological AI developers look for higher-quality training and analysis inputs rather than only summarized study results [Genetic Engineering & Biotechnology News, November 2026] [SiliconANGLE, November 2026]. Founded in 2024 in San Diego by three former Verily colleagues, the company is early but notable because the founding team sits close to both the data-generation problem and the enterprise adoption problem inside life sciences workflows [Genetic Engineering & Biotechnology News, November 2026].
The current product suite centers on Tesorai Search for raw DDA and DIA mass-spectrometry files, alongside Tesorai Chat for conversational analysis and Tesorai Trove for curated public proteomics datasets; the main reported differentiation is a focus on raw experimental files rather than downstream summaries alone [SiliconANGLE, November 2026] [tesorai.com]. That positioning matters if the company can show that raw-file processing consistently improves identification, reuse, and cross-study comparison, though most public evidence on product performance still comes from company-linked materials and coverage based on company disclosures [bioRxiv, August 2024] [tesorai.com].
The team pedigree is one of the cleaner parts of the story. CEO Melissa Miao previously led business initiatives and strategic partnerships at Verily, CTO Peter Cimermancic previously led AI teams there, and CSO Charlie Kim launched and led Verily's Molecular Science program before the three founded Tesorai together [Genetic Engineering & Biotechnology News, November 2026].
On financing, Tesorai disclosed a $5.3 million seed round in November 2026 and said total funding has reached $8 million, with reported backers including Perplexity Fund, IQT, South Central Ventures, New Stack Ventures, NextGen Venture Partners, f7 Ventures, VitalStage Ventures, and ZAKA [WFMZ / PR Newswire, November 2026] [Crunchbase] [recodex.pro]. The business model is SaaS, and the company says it has signed contracts with biopharmaceutical and research organizations, but public customer detail remains thin, so the next 12 to 18 months will likely turn on proof of repeatable commercial adoption, broader workflow coverage beyond proteomics, and independent validation that the platform's raw-data approach produces durable advantages in research productivity or model readiness [Genetic Engineering & Biotechnology News, November 2026] [SiliconANGLE, November 2026].
Single-source, plausible -- Core company, team, and funding facts are corroborated by independent coverage and Crunchbase, but several material product and traction claims remain company-linked or based on single-source reporting.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Total disclosed funding of about $8 million |
The Company in Brief
PUBLIC
Tesorai is a San Diego-based startup founded in 2024, according to its Crunchbase profile and company website [Crunchbase] [tesorai.com]. The plain-language proposition is straightforward: it is building software to turn raw proteomics and related molecular research data into structured, searchable information that researchers can analyze and reuse more easily [tesorai.com].
The company presents itself as an AI platform for mass spectrometry proteomics data analysis, with an initial emphasis on making difficult-to-search experimental data usable in downstream research workflows [tesorai.com]. Public materials also identify the founding team as Melissa Miao, Peter Cimermancic, and Charlie Kim, each previously affiliated with Verily, although the company overview here stays to the basic corporate outline supported by Crunchbase and the website itself [Crunchbase] [tesorai.com].
On the public record, the key milestone sequence is still short. The company was founded in 2024 [Crunchbase] [tesorai.com]. By late 2026, Crunchbase listed Tesorai as a seed-stage company with disclosed financing activity, and the company website had formalized its product positioning around AI-enabled proteomics analysis and searchable molecular data workflows [Crunchbase] [tesorai.com]. That is early, but it is enough to establish a clear starting point: a recently formed life sciences software company with a defined wedge in proteomics data infrastructure [tesorai.com].
Confirmed across multiple sources -- Confirmed by Crunchbase and company website.
What They Have Built
Mixed sourcing
Tesorai is positioning itself around a specific bottleneck in life-sciences software: raw proteomics files are plentiful, but they are hard to search, compare, and reuse once they leave the instrument pipeline [Genetic Engineering & Biotechnology News, November 2026]. Public product descriptions point to a cloud-based platform that converts raw proteomics and related molecular-research data into structured, analysis-ready information, with the initial wedge in mass-spectrometry proteomics [Genetic Engineering & Biotechnology News, November 2026] [SiliconANGLE, November 2026]. The product suite described in press consists of Tesorai Search for processing and searching raw DDA and DIA mass-spectrometry files, Tesorai Chat for conversational downstream analysis, and Tesorai Trove for a curated catalog of public proteomics datasets used in validation and cross-study comparison [SiliconANGLE, November 2026].
The technical claim that matters most is not generic AI usage, but where the system sits in the workflow. According to SiliconANGLE, Tesorai emphasizes analysis of raw experimental files rather than relying only on summarized outputs from papers or prior studies, which, if borne out in practice, would place the company closer to core data infrastructure than to a thin reporting layer [SiliconANGLE, November 2026]. The company also states that Tesorai Search has been peer-reviewed in the Journal of Molecular Biology, and a bioRxiv preprint describes a large pretrained model for mass-spectrometry proteomics that improves identifications without requiring Percolator, with the model publicly available through the company site [Tesorai, Unknown] [bioRxiv, August 2024]. Pricing posted on the FAQ page starts at $20 per month for Plus and $100 per month for Pro, with enterprise plans offered separately, although those entry prices should be read as self-reported and not as evidence of enterprise deployment depth [Tesorai, Unknown].
A few implementation details are visible, but the stack is still only partially exposed. Tesorai says Search is built on cloud-native infrastructure that scales dynamically, and source materials tied to the research publication describe processing on Nvidia T4 GPUs and training on 21 public datasets generated on Orbitrap instruments [Tesorai, Unknown] [bioRxiv, August 2024]. The careers page shows at least one opening for a senior AI/ML research role, which supports the view that model development remains central to the product rather than peripheral to it [Tesorai, Unknown].
Unconfirmed -- This section relies materially on company website claims and press coverage, with partial support from a bioRxiv preprint and company-cited publication references [SiliconANGLE, November 2026] [Genetic Engineering & Biotechnology News, November 2026] [bioRxiv, August 2024] [Tesorai].
Market Size and Demand
From the public record
This market matters now because labs already generate large volumes of proteomics and molecular data, while the bottleneck has shifted from data creation to data searchability, reuse, and downstream interpretation [Genetic Engineering & Biotechnology News, November 2026] [SiliconANGLE, November 2026].
The available public record does not provide a named third-party TAM for Tesorai’s exact category, so the cleaner way to frame the market is through adjacent demand signals rather than force precision that the sources do not support. Tesorai is positioned around raw proteomics and molecular-research data analysis for biopharmaceutical companies, research institutions, and developers of biological AI models [Genetic Engineering & Biotechnology News, November 2026]. That places it at the intersection of research software, bioinformatics tooling, and life sciences AI infrastructure, with the company’s initial wedge in raw mass-spectrometry proteomics workflows [SiliconANGLE, November 2026].
The demand case rests less on headline market size and more on workflow friction that public sources describe consistently. SiliconANGLE reports that Tesorai focuses on raw experimental files rather than summarized outputs, which suggests a pain point in harmonizing historical and newly generated mass-spectrometry data across studies [SiliconANGLE, November 2026]. Genetic Engineering & Biotechnology News separately describes buyers using the platform for drug discovery, biomarker validation, and product characterization, all of which are settings where data standardization and searchability can affect both throughput and reproducibility [Genetic Engineering & Biotechnology News, November 2026].
A second tailwind is the rise of biological AI, but the relevant point here is data quality rather than model novelty. Public coverage repeatedly frames Tesorai as serving teams that need structured, analysis-ready molecular datasets, including companies developing biological AI models [Genetic Engineering & Biotechnology News, November 2026] [SiliconANGLE, November 2026]. If that framing holds, the company is selling into an adjacent infrastructure need: preparing fragmented experimental data so it can be queried by scientists and used more reliably in model development.
The nearest adjacent markets are laboratory data platforms, proteomics analysis software, translational bioinformatics tools, and broader multi-omics data infrastructure. Tesorai’s stated plan to extend beyond proteins to other molecular data broadens the theoretical addressable market, but public sources do not yet establish commercial traction outside proteomics, so that expansion is better treated as roadmap than current market proof [WFMZ / PR Newswire, November 2026]. In practical terms, the current market appears narrower and more specific: organizations with meaningful back catalogs of raw mass-spectrometry data and enough internal R&D intensity to pay for better retrieval, comparison, and downstream analysis [SiliconANGLE, November 2026].
Regulatory and macro conditions are supportive in a general sense, though the sourcing here remains indirect. Drug discovery teams continue to face pressure to improve research productivity, reuse existing datasets, and generate stronger validation evidence before advancing programs, which aligns with the use cases cited in public coverage [Genetic Engineering & Biotechnology News, November 2026]. At the same time, life sciences software budgets can be sensitive to longer enterprise adoption cycles and proof-of-value requirements, especially when tools sit close to established bioinformatics workflows rather than replacing them outright. That makes this an attractive market if workflow gains are measurable, but not one where broad category enthusiasm alone is likely to compress sales friction.
| Market lens | Public evidence | What it suggests |
|---|---|---|
| Core wedge | Raw mass-spectrometry proteomics data analysis [SiliconANGLE, November 2026] | Initial market is specialized rather than horizontal |
| Buyer set | Biopharma, research institutions, biological AI developers [Genetic Engineering & Biotechnology News, November 2026] | Demand can come from both internal R&D teams and model-building organizations |
| Expansion path | Broader molecular data beyond proteins [WFMZ / PR Newswire, November 2026] | Larger long-term scope, but still roadmap-based in public evidence |
| Workflow value | Searchable, structured, analysis-ready data from raw files [Genetic Engineering & Biotechnology News, November 2026] [SiliconANGLE, November 2026] | Market pull is tied to data usability and reuse, not only primary data generation |
The table points to a market that is credible but still best understood as workflow software for a specific scientific bottleneck, not as a broad life sciences platform category with established public sizing. That keeps the upside interesting, while also making proof of repeatable adoption the central market question.
Single-source, plausible -- Based primarily on two public publisher reports and one company-distributed financing announcement, with no named third-party market sizing study in the cited materials.
Who Else Is Fighting for This
MIXED Tesorai appears to be positioning itself less as a general life-sciences AI application and more as an infrastructure layer for turning raw proteomics files into searchable, reusable data, which places it closer to specialized analysis software and data-platform vendors than to broad drug-discovery model companies [SiliconANGLE, November 2026] [Genetic Engineering & Biotechnology News, November 2026].
The competitive map is easiest to read in three layers. First are incumbent proteomics analysis workflows, which in Tesorai's own framing include conventional tools used before downstream interpretation, with the company arguing that its system can improve peptide and protein identification without relying on tools such as Percolator [bioRxiv, August 2024] [tesorai.com]. Second are specialist challengers building software around raw experimental data and cloud workflows, a segment where Tesorai Search, Tesorai Chat, and Tesorai Trove are meant to operate as an integrated stack for processing, analysis, and dataset reuse [SiliconANGLE, November 2026]. Third are adjacent substitutes, namely biopharma teams and biological AI developers that assemble training data internally rather than licensing an external platform, especially when they already control enough proprietary experimental data to justify in-house tooling [Genetic Engineering & Biotechnology News, November 2026].
Tesorai's clearest edge today is the combination of founder-market fit and a narrow initial wedge. Melissa Miao, Peter Cimermancic, and Charlie Kim previously worked together at Verily, with backgrounds spanning business partnerships, AI leadership, and molecular science, which is a credible mix for selling into research environments that require both technical trust and workflow understanding [Genetic Engineering & Biotechnology News, November 2026]. The product also appears to start at the raw-file layer, not only at the level of summarized results, and the August 2024 bioRxiv paper gives at least some public technical basis for that claim [bioRxiv, August 2024] [SiliconANGLE, November 2026]. That edge looks durable if raw data ingestion and model performance compound with usage, but perishable if larger platform vendors or well-resourced biopharma informatics teams replicate the workflow faster than Tesorai can establish default status inside customer organizations.
The main exposure is commercial, not scientific. Public coverage says Tesorai has signed contracts with biopharmaceutical and research organizations and has named collaborations with MD Anderson Cancer Center, New York University, and the Michael J. Fox Foundation, but the available reporting does not clarify whether those relationships are paid production deployments, research collaborations, or narrower access arrangements [Genetic Engineering & Biotechnology News, November 2026] [citybiz.co]. That leaves an opening for incumbents already embedded in core lab and informatics workflows to defend their position through procurement familiarity and switching costs. It also leaves Tesorai exposed to adjacent AI-data companies with deeper balance sheets if customers decide the priority is broad multi-omics data infrastructure rather than a proteomics-first entry point [WFMZ / PR Newswire, November 2026].
Over the next 18 months, the most plausible competitive scenario is bifurcation rather than winner-take-all. Tesorai is the likely winner if buyers continue to prioritize raw proteomics usability, especially where historical mass-spectrometry files are valuable but underused, because that is the problem the company has described most concretely in public and where its product narrative is sharpest [SiliconANGLE, November 2026] [Genetic Engineering & Biotechnology News, November 2026]. Tesorai is the likely loser if the category shifts toward broader end-to-end molecular data platforms before it proves repeatable enterprise adoption, since the company has only seed-scale disclosed funding of about $8 million and has not yet shown a public roster of large commercial accounts that would signal channel control or standard-setting power [WFMZ / PR Newswire, November 2026].
Opportunity
PUBLIC
The prize here is not another point tool for omics workflows, but a chance to become the data layer that makes raw proteomics files usable for drug discovery, biomarker work, and biological AI training at industrial scale [Genetic Engineering & Biotechnology News, November 2026] [SiliconANGLE, November 2026].
The headline opportunity is straightforward: if Tesorai can turn difficult-to-query mass spectrometry files into searchable, structured, analysis-ready data faster and with better identification performance than incumbent workflows, it has a path to becoming default infrastructure for proteomics informatics across biopharma and research settings [SiliconANGLE, November 2026] [Tesorai Search: Large pretrained model boosts identifications in mass spectrometry proteomics without the need for Percolator | bioRxiv, August 2024]. That outcome is still early rather than established, but it is reachable for two reasons visible in the public record. First, the company is attacking raw experimental data, which is where reuse, harmonization, and downstream model training often break down [SiliconANGLE, November 2026]. Second, the founding team comes from Verily, with backgrounds spanning commercial partnerships, AI leadership, and molecular science program building, which is relevant to selling into technically demanding life sciences buyers [Genetic Engineering & Biotechnology News, November 2026].
The growth paths are still narrow, but they are legible enough to map.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Raw proteomics system of record | Tesorai Search becomes the default cloud workflow for processing and searching raw DDA and DIA files across new and historical experiments, then expands account scope from analysis into teamwide data standardization | A visible set of reference deployments or collaborations with major research institutions and biopharma groups converts the product from specialist utility into a repeatable platform sale [Genetic Engineering & Biotechnology News, November 2026] [citybiz.co] | The product is already positioned around raw-file ingestion and search, not just secondary reporting, and the company says it has signed contracts with biopharmaceutical and research organizations [SiliconANGLE, November 2026] [Genetic Engineering & Biotechnology News, November 2026] |
| Training-data backbone for biological AI | Tesorai Trove and related data structuring tools become a preferred source of harmonized proteomics datasets for companies building biological AI models | Growth in model-building demand raises the value of curated, structured molecular datasets that can be compared across studies [SiliconANGLE, November 2026] [Genetic Engineering & Biotechnology News, November 2026] | Public coverage already frames biological AI developers as a target buyer segment, and Trove is described as a curated catalog for validation and cross-study comparison [Genetic Engineering & Biotechnology News, November 2026] [SiliconANGLE, November 2026] |
| Multi-omics research operating layer | Tesorai uses proteomics as the wedge, then extends into other molecular data types and sells a broader research-data platform | Product expansion beyond proteins, funded by the seed round, gives the company a larger workflow footprint inside existing accounts [WFMZ / PR Newswire, November 2026] | The company said the new capital would support expansion beyond proteins to other molecular data, which suggests management is already building toward a broader platform, not a single-modality endpoint [WFMZ / PR Newswire, November 2026] |
These scenarios share the same underlying logic. Tesorai does not need to win all computational biology workflows to matter. It needs to own one painful bottleneck, raw proteomics data processing and reuse, and use that control point to move upstream into data ingestion and downstream into analysis, validation, and model-development workflows [SiliconANGLE, November 2026].
What compounding could look like is a data and workflow flywheel. More raw files processed through Tesorai Search should improve the usefulness of structured outputs, make Tesorai Chat more relevant for downstream analysis, and increase the value of Tesorai Trove as a comparative reference layer [SiliconANGLE, November 2026]. If that loop works, each new customer adds not only subscription revenue but also more context for model refinement, more proof points for scientific reproducibility, and more reasons for adjacent teams to standardize on the same platform. The public evidence is still early, but there are first signs of this architecture: Search, Chat, and Trove are presented as linked products rather than separate applications, and the company has reported contracts plus collaborations with organizations including MD Anderson Cancer Center, New York University, and the Michael J. Fox Foundation [SiliconANGLE, November 2026] [Genetic Engineering & Biotechnology News, November 2026] [citybiz.co].
The size of the win depends on whether Tesorai becomes software infrastructure or remains a specialist analysis layer. No credible public market-sizing figure was confirmed in the source set, so the cleaner framing is strategic value rather than TAM math. If the company becomes the default proteomics data layer for biopharma and research institutions, it could resemble the kind of vertical scientific-software asset that commands outsized value because it sits between raw experimental generation and high-value R&D decisions (scenario, not a forecast). The public support for that upside is not revenue scale yet, but the combination of an $8 million total funding base, a technically specific wedge, a peer-reviewed search product, and founder-market fit from Verily makes the upside case more concrete than a generic life sciences AI claim [WFMZ / PR Newswire, November 2026] [Tesorai | Tesorai Search: Cloud-based Database Search Engine Boosts Identifications for Mass Spectrometry Proteomics With a Pretrained Peptide-spectrum Deep-learning Model] [Genetic Engineering & Biotechnology News, November 2026].
Single-source, plausible -- This section relies on a mix of independent reporting from Genetic Engineering & Biotechnology News and SiliconANGLE, plus company-linked publication claims for product validation.
Sources
From the public record
[tesorai.com] Tesorai | AI Proteomics Platform for Mass Spec Data Analysis | https://www.tesorai.com/
[Genetic Engineering & Biotechnology News, November 2026] Former Verily Leaders Build AI Platform to Get More from Proteomics Data | https://www.genengnews.com/topics/artificial-intelligence/former-verily-leaders-build-ai-platform-to-get-more-from-proteomics-data/
[Crunchbase] Tesorai | Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/tesorai
[WFMZ / PR Newswire, November 2026] Tesorai Raises $5.3 Million to Put Vast Troves of Untapped Research Data to Work | https://www.wfmz.com/news/pr_newswire/pr_newswire_stocks/tesorai-raises-5-3-million-to-put-vast-troves-of-untapped-research-data-to-work/article_ffef9a27-3563-58a5-9f4e-dacdbb62f137.html
[SiliconANGLE, November 2026] Tesorai raises $5.3M to feed starving AI models with biological data and accelerate drug discovery | https://www.siliconangle.com/2026/11/18/tesorai-raises-5-3m-to-feed-starving-ai-models-with-biological-data-and-accelerate-drug-discovery/
[bioRxiv, August 2024] Tesorai Search: Large pretrained model boosts identifications in mass spectrometry proteomics without the need for Percolator | https://www.biorxiv.org/content/10.1101/2024.08.30.610440v1
[recodex.pro] Tesorai raises $5.3M seed round to unlock raw lab data | https://recodex.pro/tesorai-raises-5-3m-seed-round-to-unlock-raw-lab-data/
[citybiz.co] Tesorai raises $5.3 Million Seed round to expand AI-powered life sciences research platform | https://www.citybiz.co/article/935676/tesorai-raises-5-3-million-seed-round-to-expand-ai-powered-life-sciences-research-platform/
Articles about Tesorai
- Tesorai's AI Platform Turns Raw Mass Spectrometry Into a Searchable Catalog — The former Verily team has raised $8 million to structure the messy, foundational data that trains biological AI models.